News
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi ...
19hon MSN
Q&A: How organoids could make gene therapy trials safer by identifying hidden risks early on
Ryuji Morizane, MD, Ph.D., of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding ...
A staffer for HHS Secretary Robert F Kennedy Jr - who drew the ire of President Donald Trump's MAGA base and was fired - ...
Ashfields care home in Rackheath donates £386 to Leon D’Souza for vital home improvements as he battles Duchenne Muscular Dystrophy.
News-Medical.Net on MSN15h
Improving gene therapy safety with human kidney organoids
Ryuji Morizane, MD, PhD, of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author ...
Learn more about whether ADMA Biologics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the Un ...
The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...
DelveInsight’s, “ Gene Therapy Competitive landscape, 2025 ,” report provides comprehensive insights about 180+ companies and 200+ drugs in Gene Therapy Competitive landscape. It covers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback